Clinical trials for BET inhibitors run ahead of the science
Several cancer clinical trials for small molecule inhibitors of BET bromodomain proteins
have been initiated. There is enthusiasm for the anti-proliferative effect of inhibiting BRD4 …
have been initiated. There is enthusiasm for the anti-proliferative effect of inhibiting BRD4 …
Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases
E Kulikowski, BD Rakai… - Medicinal research …, 2021 - Wiley Online Library
Clinical development of bromodomain and extra‐terminal (BET) protein inhibitors differs
from the traditional course of drug development. These drugs are simultaneously being …
from the traditional course of drug development. These drugs are simultaneously being …
Maternal dysglycaemia, changes in the infant's epigenome modified with a diet and physical activity intervention in pregnancy: Secondary analysis of a randomised …
Background Higher maternal plasma glucose (PG) concentrations, even below gestational
diabetes mellitus (GDM) thresholds, are associated with adverse offspring outcomes, with …
diabetes mellitus (GDM) thresholds, are associated with adverse offspring outcomes, with …
Epigenetic drug discovery: breaking through the immune barrier
Immune-mediated diseases are clinically heterogeneous but they share genetic and
pathogenic mechanisms. These diseases may develop from the interplay of genetic factors …
pathogenic mechanisms. These diseases may develop from the interplay of genetic factors …
Beating the odds: BETs in disease
CY Wang, P Filippakopoulos - Trends in biochemical sciences, 2015 - cell.com
Bromodomains (BRDs) are evolutionarily conserved protein interaction modules that
specifically recognise acetyl-lysine on histones and other proteins, facilitating roles in …
specifically recognise acetyl-lysine on histones and other proteins, facilitating roles in …
BET bromodomain proteins are required for glioblastoma cell proliferation
Epigenetic proteins have recently emerged as novel anticancer targets. Among these,
bromodomain and extra terminal domain (BET) proteins recognize lysine-acetylated …
bromodomain and extra terminal domain (BET) proteins recognize lysine-acetylated …
MHC and Evolution in Teleosts
U Grimholt - Biology, 2016 - mdpi.com
Major histocompatibility complex (MHC) molecules are key players in initiating immune
responses towards invading pathogens. Both MHC class I and class II genes are present in …
responses towards invading pathogens. Both MHC class I and class II genes are present in …
BET bromodomain proteins Brd2, Brd3 and Brd4 selectively regulate metabolic pathways in the pancreatic β-cell
JT Deeney, AC Belkina, OS Shirihai, BE Corkey… - PloS one, 2016 - journals.plos.org
Displacement of B romodomain and E xtra-T erminal (BET) proteins from chromatin has
promise for cancer and inflammatory disease treatments, but roles of BET proteins in …
promise for cancer and inflammatory disease treatments, but roles of BET proteins in …
BRD4 regulates metastatic potential of castration-resistant prostate cancer through AHNAK
The inevitable progression of advanced prostate cancer to castration resistance, and
ultimately to lethal metastatic disease, depends on primary or acquired resistance to …
ultimately to lethal metastatic disease, depends on primary or acquired resistance to …
BET protein inhibitor JQ1 inhibits growth and modulates WNT signaling in mesenchymal stem cells
S Alghamdi, I Khan, N Beeravolu, C McKee… - Stem Cell Research & …, 2016 - Springer
Background Efficacy and safety of anticancer drugs are traditionally studied using cancer
cell lines and animal models. The thienodiazepine class of BET inhibitors, such as JQ1, has …
cell lines and animal models. The thienodiazepine class of BET inhibitors, such as JQ1, has …